APA (7th ed.) Citation

Yarza, R., Garralda, E., Sánchez Perez, V., De Velasco Oria, G., Lorusso, P., Rodríguez, R., . . . Yap, T. (2025). 1000TiP Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies. Annals of Oncology, 36, S653. https://doi.org/10.1016/j.annonc.2025.08.1569

Chicago Style (17th ed.) Citation

Yarza, R., et al. "1000TiP Novel Next Generation PARP1-selective and CNS Penetrant Inhibitor DSB2455: A Phase Ia/Ib Open Label, Multi-centre Dose Escalation Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity as Monotherapy in Participants with Advanced Malignancies." Annals of Oncology 36 (2025): S653. https://doi.org/10.1016/j.annonc.2025.08.1569.

MLA (9th ed.) Citation

Yarza, R., et al. "1000TiP Novel Next Generation PARP1-selective and CNS Penetrant Inhibitor DSB2455: A Phase Ia/Ib Open Label, Multi-centre Dose Escalation Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity as Monotherapy in Participants with Advanced Malignancies." Annals of Oncology, vol. 36, 2025, p. S653, https://doi.org/10.1016/j.annonc.2025.08.1569.